Cilostazol
- Generic Name
- Cilostazol
- Brand Names
- -
- Drug Type
- Small Molecule
- Chemical Formula
- C20H27N5O2
- CAS Number
- 73963-72-1
- Unique Ingredient Identifier
- N7Z035406B
- Background
Cilostazol is a quinolinone derivative and antiplatelet agent with vasodilating properties that has been used in the symptomatic treatment of intermittent claudication in patients with peripheral ischaemia. It is marketed under the brand name Pletal by Otsuka Pharmaceutical Co.. Cilostazol works by inhibiting both primary and secondary aggregation and reduci...
- Indication
Indicated for the alleviation of symptoms of intermittent claudication (pain in the legs that occurs with walking and disappears with rest).
- Associated Conditions
- Intermittent Claudication
- Associated Therapies
- -
Effect of Cilostazol on Endothelial Progenitor Cells and Endothelial Function in Coronary Artery Disease
- First Posted Date
- 2014-06-26
- Last Posted Date
- 2015-10-14
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 300
- Registration Number
- NCT02174939
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
Safety and Efficacy Study of Cilostazol to Treat Vasospastic Angina
- First Posted Date
- 2014-03-21
- Last Posted Date
- 2016-01-29
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 65
- Registration Number
- NCT02094469
- Locations
- 🇰🇷
Yangsan Busan University Hospital, Busan, Korea, Republic of
A Therapeutic Confirmatory Study to Evaluate the Efficacy and Safety of Cilostazol in Subjects With Vasospastic Angina
- First Posted Date
- 2014-03-14
- Last Posted Date
- 2017-05-04
- Lead Sponsor
- Korea Otsuka Pharmaceutical Co., Ltd.
- Target Recruit Count
- 100
- Registration Number
- NCT02087007
- Locations
- 🇰🇷
Yangsan Busan University Hospital, Busan, Korea, Republic of
Cilostazol Stroke Prevention Study for Antiplatelet Combination
- Conditions
- Interventions
- First Posted Date
- 2013-11-26
- Last Posted Date
- 2019-03-28
- Lead Sponsor
- Japan Cardiovascular Research Foundation
- Target Recruit Count
- 1884
- Registration Number
- NCT01995370
- Locations
- 🇯🇵
Japan Cardiovascular Research Foundation, Osaka, Japan
OPTImal Management of Antithrombotic Agents: OPTIMA-2 Trial
- Conditions
- Interventions
- First Posted Date
- 2013-10-07
- Last Posted Date
- 2020-08-18
- Target Recruit Count
- 1724
- Registration Number
- NCT01955200
- Locations
- 🇨🇳
First Affiliated Hospital of Nanjing Medical University, Nanjing, Jiangsu, China
Effect of Cilostazol Endothelial Progenitor Cells and Collateral Formation in Peripheral Occlusive Artery Disease (PAOD)
- Conditions
- Interventions
- First Posted Date
- 2013-09-30
- Last Posted Date
- 2014-07-18
- Lead Sponsor
- National Cheng-Kung University Hospital
- Target Recruit Count
- 44
- Registration Number
- NCT01952756
- Locations
- 🇨🇳
National Cheng Kung University Hospital, Tainan, Taiwan
Efficacy Study of Cilostazol and Aspirin on Cerebral Small Vessel Disease
- First Posted Date
- 2013-08-30
- Last Posted Date
- 2019-08-08
- Lead Sponsor
- Inha University Hospital
- Target Recruit Count
- 255
- Registration Number
- NCT01932203
- Locations
- 🇰🇷
Dongtan Sacred Heart Hospital, Hallym University College of Medicine, Hwaseong-si, Gyeonggi-do, Korea, Republic of
🇰🇷Hallym University Medical Center, Anyang, Korea, Republic of
🇰🇷Eulji University School of Medicine, Daejeon, Korea, Republic of
Cilostazol and Its Effects on Resumption of Meiosis in the Human Ovary
- First Posted Date
- 2013-08-02
- Last Posted Date
- 2015-05-12
- Lead Sponsor
- University of Southern California
- Target Recruit Count
- 4
- Registration Number
- NCT01915069
- Locations
- 🇺🇸
University of Southern California Fertility Clinic, Los Angeles, California, United States
Efficacy and Safety of Cilostazol in Patients of Vascular Cognitive Impairment-no Dementia (VCIND)
- First Posted Date
- 2013-06-07
- Last Posted Date
- 2013-06-07
- Lead Sponsor
- Huashan Hospital
- Target Recruit Count
- 200
- Registration Number
- NCT01872858
- Locations
- 🇨🇳
Dept. of Neurology, Huashan Hospital, Fudan University, Shanghai, Shanghai, China
Pharmacodynamic Drug Interaction Between Cilostazol and Statins
- First Posted Date
- 2013-06-06
- Last Posted Date
- 2015-05-27
- Lead Sponsor
- Samsung Medical Center
- Target Recruit Count
- 63
- Registration Number
- NCT01870466
- Locations
- 🇰🇷
Samsung Medical Center, Seoul, Korea, Republic of
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.